Related Experiment Video

Updated: May 20, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

12.9K

Advances in the treatment of metastatic prostate cancer in China

Baojun Wang1, Zhenhua Liu2, Luyao Yang2

  • 1Department of Urology, Chinese PLA General Hospital, Beijing 100853, China.

Cancer Biology & Medicine
|May 19, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

4.4K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.0K

Related Experiment Videos

Last Updated: May 20, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

12.9K
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

4.4K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Cancer Therapies02:49

Cancer Therapies

7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K

Articles linked to this work by shared authors, journal, and citation graph.

Integrative quality evaluation of tea raw material uniformity using sensory analysis, metabolomics, GC-O, and principal component analysis.

Food chemistry·2026

Exon-6 truncated p53 Suppresses Innate Immune Responses to Facilitate Immune Evasion in Bladder Cancer.

International journal of biological sciences·2026

Sensory neuron-derived CGRP ameliorates kidney injury and fibrosis via monocytes and macrophages.

Cell research·2026

Dual-mode detection of tetracyclines in animal-derived food samples based on MOF-on-MOF heterostructure fluorescent sensor coupled with machine learning algorithms.

Food chemistry·2026

RADMorph: A region-aware deformable registration network for organ-specific thoracic CT alignment.

Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society·2026

Case report: Systemic T-DXd and bevacizumab plus local therapy prolongs survival in breast cancer leptomeningeal metastasis: a case series and literature review.

Frontiers in oncology·2026

Efbemalenograstim alfa as prophylaxis for chemotherapy-induced neutropenia in patients with non-small-cell lung cancer: a randomized, multicenter, phase II trial.

Cancer biology & medicine·2026

Revisiting the immunosuppressive microenvironment in hepatocellular carcinoma: a functional taxonomy of immune cells and therapeutic targeting.

Cancer biology & medicine·2026

Migrasome-propagated ITGβ3-TGFβ1 circuit orchestrates breast cancer brain metastasis by reprogramming the microglial niche.

Cancer biology & medicine·2026

cGAS-STING pathway activation drives the cold-to-hot tumor transition and sensitizes immunotherapy.

Cancer biology & medicine·2026

Global landscape and temporal trends in lifetime risk of colorectal cancer in 185 countries: a population-based study.

Cancer biology & medicine·2026

FDX1 expression promotes DSF/Cu-induced cuproptosis in gastric cancer cells.

Cancer biology & medicine·2026

Time to Treatment Failure as a Recorded Treatment-Process Measure in C-CAT. Reply to Comment on "Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462".

Current oncology (Toronto, Ont.)·2026

Does Time to Treatment Failure Measure the Same Clinical Process Across Oncology Facilities? Comment on Kajiura et al. Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462.

Current oncology (Toronto, Ont.)·2026

Electroacupuncture Combined with Cognitive Behavioral Therapy for Insomnia Alleviates Insomnia-Anxiety Comorbidity in Gynecological Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial.

Current oncology (Toronto, Ont.)·2026

[177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.

Current oncology (Toronto, Ont.)·2026

A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.

Current oncology (Toronto, Ont.)·2026

A Remotely Delivered Exercise-Based Rehabilitation Program for Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy (EX-CIPN): A Phase I Feasibility Trial.

Current oncology (Toronto, Ont.)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us